{{Drugbox
| verifiedrevid = 460111355
| IUPAC_name = 4-(5''H''-dibenzo [a,d]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride
| image = Cyproheptadine.svg
| width = 175
| image2 = Cyproheptadine-Spartan-PM3-3D-balls.png
| width2 = 175
<!--Clinical data-->
| pronounce = ({{IPAc-en|ˌ|s|aɪ|p|r|oʊ|ˈ|h|ɛ|p|t|ə|d|iː|n}}{{refn|{{Dictionary.com|Cyproheptadine}}}}
| tradename = Periactin, others
| Drugs.com = {{drugs.com|monograph|cyproheptadine-hydrochloride}}
| MedlinePlus = a682541
| DailyMedID = 54686520-506f-7765-7220-436f736d6963
| pregnancy_AU = A
| pregnancy_US = B
| legal_AU  = S3
| legal_CA = OTC
| legal_UK = GSL
| legal_US = Rx-only
| routes_of_administration = [[Oral administration|Oral]]
<!--Pharmacokinetic data-->
| protein_bound = 96 to 99%
| metabolism = [[Liver|Hepatic]].<ref name = DM>{{cite web|title=CYPROHEPTADINE HYDROCHLORIDE tablet [Boscogen, Inc.]|work=DailyMed|publisher=Boscogen, Inc.|date=November 2010|accessdate=26 October 2013|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f90faaa3-f40f-4653-8fb8-144d61c6b1d4|format=PDF}}</ref><ref name = TGA>{{cite web|title=PRODUCT INFORMATION PERIACTIN® (cyproheptadine hydrochloride)|work=Aspen Pharmacare Australia|publisher=Aspen Pharmacare Australia Pty Ltd|date=17 November 2011|accessdate=26 October 2013|url=http://www.aspenpharma.com.au/product_info/pi/Periactin_PI_17Nov11.pdf}}</ref> Mostly [[CYP3A4]] mediated.
| elimination_half-life = 8.6 hours<ref name="pmid15083941">{{cite journal |vauthors=Gunja N, Collins M, Graudins A | title = A comparison of the pharmacokinetics of oral and sublingual cyproheptadine | journal = Journal of Toxicology. Clinical Toxicology | volume = 42 | issue = 1 | pages = 79–83 | year = 2004 | pmid = 15083941 | doi = 10.1081/clt-120028749| url = }}</ref>
| excretion = Faecal (2-20%; 34% of this as unchanged drug) and [[renal]] (40%; none as unchanged drug)<ref name = DM/><ref name = TGA/>
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 129-03-3
| CAS_supplemental = {{CAS|969-33-5}} ([[hydrochloride]])
| ATC_prefix = R06
| ATC_suffix = AX02
| PubChem = 2913
| IUPHAR_ligand = 277
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00434
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2810
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2YHB6175DO
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07765
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4046
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 516
<!--Chemical data-->
| C=21 | H=21 | N=1
| molecular_weight = 287.398 g/mol
| SMILES = c43\C(=C1/CCN(C)CC1)c2ccccc2\C=C/c3cccc4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JJCFRYNCJDLXIK-UHFFFAOYSA-N
}}

'''Cyproheptadine''', sold under the brand name '''Periactin''' among others, is a [[first-generation antihistamine|first-generation]] [[antihistamine]] with additional [[anticholinergic]], [[antiserotonergic]], and [[local anesthetic]] properties.

==Medical uses==
[[File:Periactin.jpg|thumb|Periactin (cyproheptadine) 4 mg tablets]]

* Cyproheptadine is used to treat allergic reactions (specifically [[hay fever]]).<ref>[http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682541.html MedlinePlus Drug Information: Cyproheptadine]</ref>  The evidence for its use for this purpose in children is weak and [[ketotifen]] and [[loratadine]] showed equal or better results in the small trials in which they have been compared.<ref name=DeBruyne2017/>

* It is sometimes used, especially in its liquid formulation, as a preventive measure against [[migraine]] in children and adolescents,<ref>{{cite journal|last1=Merison|first1=K|last2=Jacobs|first2=H|title=Diagnosis and Treatment of Childhood Migraine.|journal=Current treatment options in neurology|date=November 2016|volume=18|issue=11|pages=48|doi=10.1007/s11940-016-0431-4|pmid=27704257}}</ref> but as of 2017 the evidence for this was weak.<ref name=DeBruyne2017>{{cite journal|last1=De Bruyne|first1=P|last2=Christiaens|first2=T|last3=Boussery|first3=K|last4=Mehuys|first4=E|last5=Van Winckel|first5=M|title=Are antihistamines effective in children? A review of the evidence.|journal=Archives of disease in childhood|date=January 2017|volume=102|issue=1|pages=56-60|doi=10.1136/archdischild-2015-310416|pmid=27335428}}</ref><ref>{{cite journal|last1=Saito|first1=Y|last2=Yamanaka|first2=G|last3=Shimomura|first3=H|last4=Shiraishi|first4=K|last5=Nakazawa|first5=T|last6=Kato|first6=F|last7=Shimizu-Motohashi|first7=Y|last8=Sasaki|first8=M|last9=Maegaki|first9=Y|title=Reconsideration of the diagnosis and treatment of childhood migraine: A practical review of clinical experiences.|journal=Brain & development|date=May 2017|volume=39|issue=5|pages=386-394|doi=10.1016/j.braindev.2016.11.011|pmid=27993427}}</ref>  This use is on the label in the UK and some other countries.<ref name=DeBruyne2017/>  In Australia this is the only indication for which cyproheptadine is subsidised by the [[Pharmaceutical Benefits Scheme|PBS]].<ref name="AMH">{{cite book | editor = Rossi, S | isbn = 978-0-9805790-9-3 | title = Australian Medicines Handbook | place = Adelaide | publisher = The Australian Medicines Handbook Unit Trust | year = 2013 | edition = 2013 }}</ref>
* It is also used off-label in the treatment of [[cyclical vomiting syndrome]] in infants; the only evidence for this use comes from retrospective studies.<ref>{{cite journal|last1=Salvatore|first1=S|last2=Barberi|first2=S|last3=Borrelli|first3=O|last4=Castellazzi|first4=A|last5=Di Mauro|first5=D|last6=Di Mauro|first6=G|last7=Doria|first7=M|last8=Francavilla|first8=R|last9=Landi|first9=M|last10=Martelli|first10=A|last11=Miniello|first11=VL|last12=Simeone|first12=G|last13=Verduci|first13=E|last14=Verga|first14=C|last15=Zanetti|first15=MA|last16=Staiano|first16=A|last17=SIPPS Working Group on|first17=FGIDs.|title=Pharmacological interventions on early functional gastrointestinal disorders.|journal=Italian journal of pediatrics|date=16 July 2016|volume=42|issue=1|pages=68|doi=10.1186/s13052-016-0272-5|pmid=27423188|pmc=4947301}}</ref>
* Cyproheptadine is sometimes used off label to improve [[akathisia]] in people on antipsychotic medications.<ref name="Maudsley">{{cite book|last1=Taylor|first1=David|last2=Paton|first2=Carol|last3=Kapur|first3=Shitij|title=The Maudsley Prescribing Guidelines in Psychiatry|date=2015|publisher=John Wiley & Sons|isbn=9781118754573|page=85|url=https://books.google.com/books?id=Lb77CAAAQBAJ|language=en}}</ref>
* It used off-label to treat various dermatological conditions, including [[psychogenic pruritus|psychogenic itch]]<ref>{{cite journal|last1=Szepietowski|first1=JC|last2=Reszke|first2=R|title=Psychogenic Itch Management.|journal=Current problems in dermatology|date=2016|volume=50|pages=124-32|doi=10.1159/000446055|pmid=27578081}}</ref>  drug-induced [[hyperhidrosis]] (excessive sweating),<ref>{{cite journal |vauthors=Ashton AK, Weinstein WL |title=Cyproheptadine for drug-induced sweating |journal=[[American Journal of Psychiatry]] |volume=159 |issue=5 |pages=874–5 |date=May 2002 |pmid=11986151 |doi= 10.1176/appi.ajp.159.5.874-a|url=http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=11986151}}</ref> and prevention of blister formation for some people with [[epidermolysis bullosa simplex]].<ref>{{cite journal|last1=Pfendner|first1=Ellen G.|last2=Bruckner|first2=Anna L.|title=Epidermolysis Bullosa Simplex|journal=GeneReviews|date=October 13, 2016|pmid=20301543|url=https://www.ncbi.nlm.nih.gov/books/NBK1369/|publisher=University of Washington, Seattle}}</ref>
* One of the side effects of the drug is increased [[appetite]] and weight gain, which has led to its off-label use for this purpose in children who are wasting as well as people with [[cystic fibrosis]]. The evidence for the efficacy in light of other side effects is weak.<ref name=DeBruyne2017/><ref>{{cite journal|last1=Chinuck|first1=R|last2=Dewar|first2=J|last3=Baldwin|first3=DR|last4=Hendron|first4=E|title=Appetite stimulants for people with cystic fibrosis.|journal=The Cochrane database of systematic reviews|date=27 July 2014|issue=7|pages=CD008190|doi=10.1002/14651858.CD008190.pub2|pmid=25064192}}</ref>
* It is sometimes used off-label in the management of moderate to severe cases of [[serotonin syndrome]], a complex of symptoms associated with the use of [[serotonergic]] drugs, such as [[selective serotonin reuptake inhibitor]]s and [[monoamine oxidase inhibitors]]),  and in cases of high levels of serotonin in the blood resulting from a serotonin-producing [[carcinoid]] tumor.<ref name = AMH/><ref>{{cite journal|last1=Iqbal|first1=MM|last2=Basil|first2=MJ|last3=Kaplan|first3=J|last4=Iqbal|first4=MT|title=Overview of serotonin syndrome.|journal=Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists|date=November 2012|volume=24|issue=4|pages=310-8|pmid=23145389}}</ref>

==Adverse effects==
'''Adverse effects include:'''<ref name = DM/><ref name = TGA/>

{{colbegin|2}}
* Sedation and sleepiness (often transient)
* Dizziness
* Disturbed coordination
* Confusion
* Restlessness
* Excitation
* Nervousness
* Tremor
* Irritability
* Insomnia
* Paresthesias
* Neuritis
* Convulsions
* Euphoria
* Hallucinations
* Hysteria
* Faintness
* Allergic manifestation of rash and edema
* Diphoresis
* Urticaria
* Photosensitivity
* Acute labyrinthitis
* Diplopia (seeing double)
* Vertigo
* Tinnitus
* Hypotension (low blood pressure)
* Palpitation
* Extrasystoles
* Anaphylactic shock
* Hemolytic anemia
* Blood dyscrasias such as [[leukopenia]], [[agranulocytosis]] and [[thrombocytopenia]]
* Cholestasis
* Hepatic (liver) side effects such as:
:- [[Hepatitis]]
:- [[Jaundice]]
:- [[Hepatic failure]]<ref>{{cite journal|last1=Chertoff|first1=Jason|title=Cyproheptadine-Induced Acute Liver Failure|journal=ACG Case Reports Journal|date=8 July 2014|volume=1|issue=4|doi=10.14309/crj.2014.56|pmc=4286888}}</ref>
:- Hepatic function abnormality
* [[Epigastric]] distress
* [[Anorexia (symptom)|Anorexia]]
* Nausea
* Vomiting
* Diarrhea
* [[Anticholinergic]] side effects such as:
:- Blurred vision
:- Constipation
:- Xerostomia (dry mouth)
:- Tachycardia (high heart rate)
:- Urinary retention
:- Difficulty passing urine
:- Nasal congestion
:- Nasal or throat dryness
* Urinary frequency
* Early menses
* Thickening of bronchial secretions
* Tightness of chest and wheezing
* Fatigue
* Chills
* Headache
* Erectle Dysfunction
* Increased appetite
* Weight gain
{{colend}}

===Overdose===
Gastric decontamination measures such as activated charcoal are sometimes recommended in cases of overdose. The symptoms are usually indicative of CNS depression (or conversely CNS stimulation in some) and excess anticholinergic side effects. The [[LD50|LD<sub>50</sub>]] in mice is 123&nbsp;mg/kg and 295&nbsp;mg/kg in rats.<ref name = DM/><ref name = TGA/>

==Pharmacology==
{| class="wikitable floatright" style="font-size:small;"
|+ Cyproheptadine<ref name="PDSP">{{cite web | title = PDSP K<sub>i</sub> Database | work = Psychoactive Drug Screening Program (PDSP) | author1 = Roth, BL | author2 = Driscol, J | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health || format = HTML | accessdate = 14 August 2017 | url = https://kidbdev.med.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=cyproheptadine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref>
|-
! Site !! K<sub>i</sub> (nM) !! Species !! Ref
|-
| [[Histamine H1 receptor|H<sub>1</sub>]] || 0.06 || Human || 
|-
| [[Histamine H2 receptor|H<sub>2</sub>]] || {{abbr|ND|No data}} || {{abbr|ND|No data}} || 
|-
| [[Histamine H3 receptor|H<sub>3</sub>]] || >10,000 || Human || 
|-
| [[Histamine H4 receptor|H<sub>4</sub>]] || 202 || Human || 
|-
| [[Muscarinic acetylcholine receptor M1|M<sub>1</sub>]] || 12 || Human || 
|-
| [[Muscarinic acetylcholine receptor M2|M<sub>2</sub>]] || 7 || Human || 
|-
| [[Muscarinic acetylcholine receptor M3|M<sub>3</sub>]] || 12 || Human || 
|-
| [[Muscarinic acetylcholine receptor M4|M<sub>4</sub>]] || 8 || Human || 
|-
| [[Muscarinic acetylcholine receptor M5|M<sub>5</sub>]] || 11.8 || Human || 
|-
| [[5-HT1A receptor|5-HT<sub>1A</sub>]] || 59 || Human || 
|-
| [[5-HT2A receptor|5-HT<sub>2A</sub>]] || 1.67 || Human || 
|-
| [[5-HT2B receptor|5-HT<sub>2B</sub>]] || 1.54 || Human || 
|-
| [[5-HT2C receptor|5-HT<sub>2C</sub>]] || 2.23 || Human || 
|-
| [[5-HT3 receptor|5-HT<sub>3</sub>]] || 228 || Mouse || 
|-
| [[5-HT6 receptor|5-HT<sub>6</sub>]] || 142 || Human || 
|-
| [[5-HT7 receptor|5-HT<sub>7</sub>]] || 123 || Human || 
|-
| [[Dopamine D1 receptor|D<sub>1</sub>]] || 117 || Human || 
|-
| [[Dopamine D2 receptor|D<sub>2</sub>]] || 112 || Human || 
|-
| [[Dopamine D3 receptor|D<sub>3</sub>]] || 8 || Human || 
|-
| {{abbrlink|SERT|Serotonin transporter}} || 4,100 || Rat || 
|-
| {{abbrlink|NET|Norepinephrine transporter}} || 290 || Rat || 
|-
| {{abbrlink|DAT|Dopamine transporter}} || {{abbr|ND|No data}} || {{abbr|ND|No data}} || 
|- class="sortbottom"
| colspan="4" | Values are K<sub>i</sub> (nM). The smaller the value,<br />the more strongly the drug binds to the site.
|}

Cyproheptadine is a very potent [[antihistamine]] or [[receptor antagonist|antagonist]] of the [[H1 receptor|H<sub>1</sub> receptor]]. At higher concentrations, it also has [[anticholinergic]], [[antiserotonergic]], and [[antidopaminergic]] activities. Of the [[serotonin receptor]]s, it is an especially potent antagonist of the [[5-HT2 receptor|5-HT<sub>2</sub> receptor]]s, and this underlies its effectiveness in the treatment of [[serotonin syndrome]].

Cyproheptadine is known to be an [[receptor antagonist|antagonist]] or [[inverse agonist]] of all of the [[receptor (biochemistry)|receptor]]s listed in the table to the right.<ref name="PDSP" />

==Pharmacokinetics==
Cyproheptadine is well-absorbed following [[oral administration|oral ingestion]], with peak plasma levels occurring after 1 to 3&nbsp;hours.<ref name="MurrayDaly2011">{{cite book | author1 = Lindsay Murray | author2 = Frank Daly | author3 = David McCoubrie |author4=Mike Cadogan | title = Toxicology Handbook | url = https://books.google.com/books?id=KDOeIldGWxQC&pg=PT388 | accessdate = 27 November 2011 | date = 15 January 2011 | publisher = Elsevier Australia | isbn = 978-0-7295-3939-5 | page = 388}}</ref> Its [[terminal half-life]] when taken orally is approximately 8&nbsp;hours.<ref name="pmid15083941" />

==Chemistry==
Cyproheptadine is a [[tricyclic]] [[benzocycloheptene]] and is closely related to [[pizotifen]] and [[ketotifen]] as well as to [[tricyclic antidepressant]]s.

==Research==
Cyproheptadine was studied in one small (N=18) trial as an adjunct in people with schizophrenia whose condition was stable and were on other medication; while attention and verbal fluency appeared to be improved, the study was too small to draw generalizations from.<ref>{{cite journal|last1=Buoli|first1=M|last2=Altamura|first2=AC|title=May non-antipsychotic drugs improve cognition of schizophrenia patients?|journal=Pharmacopsychiatry|date=March 2015|volume=48|issue=2|pages=41-50|doi=10.1055/s-0034-1396801|pmid=25584772}}</ref>  It has also been studied as an adjuvant in two other trials in people with schizophrenia, around fifty people overall, and did not appear to have an effect.<ref name=Dabaghzadeh2012/>

There have been some trials to see if cyproheptadine could reduce sexual dysfunction caused by antipsychotics; it failed to show an effect.<ref>{{cite journal|last1=Nunes|first1=LV|last2=Moreira|first2=HC|last3=Razzouk|first3=D|last4=Nunes|first4=SO|last5=Mari Jde|first5=J|title=Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review.|journal=Journal of sex & marital therapy|date=2012|volume=38|issue=3|pages=281-301|doi=10.1080/0092623X.2011.606883|pmid=22533871}}</ref>

As of 2012, descriptions of the use of cyproheptadine to reduce the number of nightmares in around 12 people with [[post-traumatic stress syndrome]] had been published; it appeared to be helpful in all of them.<ref name=Dabaghzadeh2012>{{cite journal|last1=Dabaghzadeh|first1=F|last2=Khalili|first2=H|last3=Ghaeli|first3=P|last4=Dashti-Khavidaki|first4=S|title=Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz.|journal=Expert opinion on pharmacotherapy|date=December 2012|volume=13|issue=18|pages=2613-24|doi=10.1517/14656566.2012.742887|pmid=23140169}}</ref>

==Veterinary use==
Cyproheptadine is used in [[cat]]s as an [[appetite stimulant]]<ref>{{cite journal|last1=Agnew|first1=W|last2=Korman|first2=R|title=Pharmacological appetite stimulation: rational choices in the inappetent cat.|journal=Journal of feline medicine and surgery|date=September 2014|volume=16|issue=9|pages=749-56|doi=10.1177/1098612X14545273|pmid=25146662}}</ref> and as an adjunct in the treatment of [[asthma]].<ref name=MVM2>{{cite book |author= Dowling PM |chapter= Systemic Therapy of Airway Disease: Cyproheptadine |chapterurl=http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/190907.htm |veditors=Kahn CM, Line S, Aiello SE |title= The Merck Veterinary Manual |date= February 8, 2005 |publisher= [[John Wiley & Sons]] |edition= 9th |isbn= 0-911910-50-6}} Retrieved on October 26, 2008.</ref> Possible adverse effects include excitement and aggressive behavior.<ref name=MVM1>{{cite book |author= Dowling PM |chapter= Drugs Affecting Appetite |chapterurl= http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/190302.htm |veditors=Kahn CM, Line S, Aiello SE |title= [[Merck Veterinary Manual|The Merck Veterinary Manual]] |date= February 8, 2005 |publisher= [[John Wiley & Sons]] |edition= 9th |isbn= 0-911910-50-6}} Retrieved on October 26, 2008.</ref>  The [[elimination half-life]] of cyproheptadine in cats is 12 hours.<ref name=MVM2/>

Cyproheptadine is a second line treatment for pituitary pars intermedia dysfunction in horses.<ref>{{cite journal|last1=Durham|first1=AE|title=Therapeutics for Equine Endocrine Disorders.|journal=The Veterinary clinics of North America. Equine practice|date=April 2017|volume=33|issue=1|pages=127-139|doi=10.1016/j.cveq.2016.11.003|pmid=28190613}}</ref><ref>{{cite web|last=Merck Vet Manual|title=Hirsutism Associated with Adenomas of the Pars Intermedia|url=http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/40504.htm|accessdate=April 24, 2011}}</ref>

==References==
{{Reflist|30em}}

{{Antihistamines}}
{{Sedatives}}
{{Appetite stimulants}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Histamine receptor modulators}}
{{Ion channel modulators}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:Antihistamines]]
[[Category:Antipsychotics]]
[[Category:Appetite stimulants]]
[[Category:Dibenzocycloheptenes]]
[[Category:Dopamine antagonists]]
[[Category:Local anesthetics]]
[[Category:Muscarinic antagonists]]
[[Category:Piperidines]]
[[Category:Serotonin antagonists]]
[[Category:Sodium channel blockers]]